Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Upadacitinib in Pediatric Subjects With Severe Alopecia Areata

NCT07772492 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07772492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07772492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Upadacitinib in Pediatric Subjects With Severe Alopecia Areata
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Recruiting
Start date
August 24, 2026
Completion date
March 31, 2032
Enrollment
300 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

severe alopecia areata